Inclusion Criteria
•	Histologically or cytologically-documented, advanced solid tumor of one of the following types:
o	Anal Squamous Cell Carcinoma
o	Biliary Adenocarcinoma (gallbladder or biliary tree (intrahepatic or extrahepatic cholangiocarcinoma) except Ampulla of Vater cancers)
o	Neuroendocrine Tumors (well- and moderately-differentiated) of the lung, appendix, small intestine, colon, rectum, or pancreas
o	Endometrial Carcinoma (sarcomas and mesenchymal tumors are excluded)
o	Cervical Squamous Cell Carcinoma
o	Vulvar Squamous Cell Carcinoma
o	Small Cell Lung Carcinoma
o	Mesothelioma
o	Thyroid Carcinoma

Exclusion Criteria
•	Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study treatment
•	Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment
•	Active autoimmune disease that has required systemic treatment in the past 2 years
•	Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or not recovered from an adverse event caused by mAbs administered more than 4 weeks earlier
•	Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks of study Day 1 or not recovered from adverse events caused by a previously administered agent
•	Known additional malignancy within 2 years prior to enrollment with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or curatively resected in situ cancers
•	Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
•	Has known glioblastoma multiforme of the brain stem
•	Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
